Search
Returning search results with filters:
Remove filter for
Category: Drugs
Remove filter for
Last updated: 2019
Remove filter for
Type: Health professional risk communication
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 7 of 7 items.
GILENYA (fingolimod) - Risk of Congenital Malformations
AlertHealth professional risk communication | 2019-12-19
XELJANZ / XELJANZ XR (tofacitinib) - Risk of Thrombosis
AlertHealth professional risk communication | 2019-12-02
ULORIC ® (febuxostat) - Increased Risk of Cardiovascular Fatal Outcomes
AlertHealth professional risk communication | 2019-11-04
LEMTRADA (alemtuzumab) - Risk of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Associated Serious Cardiovascular Reactions
AlertHealth professional risk communication | 2019-10-15
Tacrolimus and the Risk of Graft Rejection due to Medication Errors: Inadvertent Switching between Different Oral Formulations
AlertHealth professional risk communication | 2019-07-22
ALERTEC (modafinil) and the Risk of Congenital Anomalies
AlertHealth professional risk communication | 2019-06-20
Important Safety Information on ACTEMRA® (tocilizumab) - Risk of Hepatotoxicity
AlertHealth professional risk communication | 2019-05-21